$266 Million is the total value of Aquilo Capital Management, LLC's 12 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 45.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Buy | SPDR SERIES TRUSTput | $118,888,000 | +211.8% | 1,250,000 | +150.0% | 44.66% | +66.3% |
| QURE | Buy | UNIQURE NV | $28,442,000 | +84.7% | 396,899 | +1.5% | 10.68% | -1.5% |
| PRQR | Buy | PROQR THRAPEUTICS N V | $19,053,000 | +297.8% | 1,922,570 | +131.2% | 7.16% | +112.2% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $17,769,000 | +76.1% | 4,966,820 | +67.9% | 6.67% | -6.1% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $15,296,000 | +78.4% | 1,166,736 | +22.6% | 5.74% | -4.8% |
| GLPG | Buy | GALAPAGOS NVspon adr | $14,885,000 | +71.5% | 71,967 | +26.6% | 5.59% | -8.5% |
| MRUS | MERUS N V | $14,626,000 | -21.0% | 1,038,746 | 0.0% | 5.49% | -57.9% | |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $13,536,000 | – | 614,436 | +100.0% | 5.08% | – |
| SPRO | SPERO THERAPEUTICS INC | $11,099,000 | -9.3% | 1,154,356 | 0.0% | 4.17% | -51.6% | |
| RGNX | New | REGENXBIO INC | $11,012,000 | – | 268,778 | +100.0% | 4.14% | – |
| FATE | FATE THERAPEUTICS INC | $1,414,000 | +26.0% | 72,273 | 0.0% | 0.53% | -32.8% | |
| MOR | New | MORPHOSYS AGsponsored ads | $217,000 | – | 6,080 | +100.0% | 0.08% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -767,026 | -100.0% | -6.15% | – |
| QURE | Exit | UNIQURE NVcall | $0 | – | -400,000 | -100.0% | -11.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.